Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy.
作者信息
Sbrana Francesco, Bigazzi Federico, Corciulo Carmen, Dal Pino Beatrice
机构信息
U.O. Lipoapheresis and Center for Inherited Dyslipidemias, Fondazione Toscana Gabriele Monasterio, Via Moruzzi, Pisa 1-56124, Italy.
出版信息
Eur J Prev Cardiol. 2024 Jun 3;31(8):e62-e64. doi: 10.1093/eurjpc/zwae054.
PMID:38470832
Abstract
摘要
Zotero 插件